Baicalein decreases uric acid and prevents hyperuricemic nephropathy in mice

Xiaolu Meng; Zhuo Mao; Xin Li; Dandan Zhong; Min Li; Yingli Jia; Jing Wei; Baoxue Yang; Hong Zhou

doi:10.18632/oncotarget.16928

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Baicalein decreases uric acid and prevents hyperuricemic nephropathy in mice

Xiaolu Meng, Zhuo Mao, Xin Li, Dandan Zhong, Min Li, Yingli Jia, Jing Wei, Baoxue Yang and Hong Zhou _

PDF | HTML | How to cite

Oncotarget. 2017; 8:40305-40317. https://doi.org/10.18632/oncotarget.16928

Metrics: PDF 2597 views | HTML 3405 views | ?

Abstract

Xiaolu Meng1, Zhuo Mao2, Xin Li3, Dandan Zhong1, Min Li1, Yingli Jia1, Jing Wei2, Baoxue Yang1 and Hong Zhou1

1Department of Pharmacology, School of Basic Medical Sciences, Peking University, Beijing, 100191, P.R. China

2Tianjin Key Laboratory for Modern Drug Delivery and High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, 300072, P.R. China

3Drug Clinical Trial Institution, The Affiliated Hospital of Qingdao University, Qingdao, 266003, P.R. China

Correspondence to:

Hong Zhou, email: [email protected]

Keywords: baicalein, hyperuricemia, uric acid, nephropathy, xanthine oxidoreductase

Received: January 06, 2017 Accepted: March 24, 2017 Published: April 07, 2017

ABSTRACT

Baicalein, a natural flavonoid, is structurally advantageous for binding to xanthine oxidoreductase. In our study, molecular docking analysis and Surface Plasmon Resonance revealed a direct interaction between baicalein and xanthine oxidoreductase. Moreover, 50 mg/kg/d baicalein treatment significantly suppressed the viability of xanthine oxidoreductase in hyperuricemia mouse model. The data showed that baicalein remarkably prevented renal dysfunction, ameliorated kidney fibrosis, alleviated epithelial-mesenchymal transition and oxidative stress in hyperuricemia mice. Thus, we concluded that baicalein executed a kidney-protection action in hyperuricemia and therefore may be used as a therapeutic alternative for hyperuricemic nephropathy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16928

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Baicalein decreases uric acid and prevents hyperuricemic nephropathy in mice

Abstract